Ulteriori informazioni
This book provides an introduction to the principles of pharmacogenomics and precision medicine, followed by the pharmacogenomics aspects of major therapeutic areas such as cardiovascular disease, cancer, organ transplantation, psychiatry, infection, antithrombotic drugs. It also includes genotyping technology and therapeutic drug monitoring in Pharmacogenomics; ethical, Legal and Regulatory Issues; cost-effectiveness of pharmacogenetics-guided treatment; application of pharmacogenomics in drug discovery and development and clinical Implementation of Pharmacogenomics for Personalized Precision Medicine. The contributors of Pharmacogenomics in Precision Medicine come from a team of experts, including professors from academic institutions and practitioner from hospital. It will give an in-depth overview of the current state of pharmacogenomics in drug therapy for all health care professionals and graduate students in the era of precision medicine.
Sommario
Chapter 1. Introduction and Principles of Pharmacogenomics and Precision medicine.- Chapter 2. Pharmacogenomics in Cardiovascular Diseases.- Chapter 3. Pharmacogenomics of Antitumor Chemotherapeutic Agents.- Chapter 4. Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy.- Chapter 5. Pharmacogenomics of Immunosuppressant.- Chapter 6. Pharmacogenomics of Psychiatric drugs.- Chapter 7. Pharmacogenomics of Anti-Infective Agents.- Chapter 8. Pharmacogenomics of Antithrombotic drugs.- Chapter 9. Pharmacogenomics in Therapeutic Drug Monitoring.- Chapter 10. Pharmacomicrobiomics.- Chapter 11. Genotyping technology in Pharmacogenomics.- Chapter 12. The Ethical, Legal and Regulatory Issues Associated with Pharmacogenomics.- Chapter 13. Cost-effectiveness of pharmacogenetic-guided treatment.- Chapter 14. Application of pharmacogenomics in drug discovery and development.- Chapter 15. Barriers and Solutions in Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine.
Info autore
Dr. Weimin Cai is a professor at the School of Pharmacy of Fudan University, China. He obtained his Ph.D from the Nanjing Medical University in 2000, and worked as a postdoctoral researcher at the School of Pharmacy at University of Kentucky in 2001. He became a full professor at School of Pharmacy, Fudan University in 2008. His research has been focused on clinical pharmacy, therapeutic drug monitoring and pharmacogenetics, fields in which he has published more than 170 research articles.
Dr. Zhaoqian Liu is a professor at Xiangya School of Medicine of Central South University, China. He obtained his Ph.D from Central South University in 2001, and worked as a postdoctoral researcher at the Walther Cancer Center of Indiana University School of Medicine from 2002 to 2004. He became a full professor in 2008. His research has been focused on pharmacogenomics, fields in which he has published more than 230 research articles.
Dr. Liyan Miao is a professor and vice president of the First Affiliated Hospital of Soochow, China. She obtained her M.D. from Suzhou Medical College in 1998, and worked as a postdoctoral researcher at the University of Mississippi Medical Center, USA from 1999 to 2002. She became a full professor in 2002. Her research has been focused on individualized drug treatment and rational drug use, fields in which she has published more than 50 research articles in recent 10 years.
Dr. Xiaoqiang Xiang is an associate professor at the School of Pharmacy of Fudan University, China. He obtained his Ph.D from University of Helsinki in 2012, and then joined School of Pharmacy of Fudan University as an associate professor. His research has been focused on clinical pharmacology and drug metabolism, fields in which he has published 23 research articles.
